periods were $5.2 million and $5.3 million, respectively. The Company had investment sales and prepayments totaling approximately $29.6 million and $85.5 million, respectively, for the three and six months ended June 30, 2017. Net realized gains over the same periods were $0.04 million and $0.1 million, respectively. Net realized losses for the three and six months ended June 30, 2018 were primarily related to the Company’s exit from its investment in Metamorph US 3, LLC. Net realized gains for the three and six months ended June 30, 2017 were related to the sale of select assets.
Net Change in Unrealized Gain (Loss)
For the three and six months ended June 30, 2018, net change in unrealized gain (loss) on the Company’s assets and liabilities totaled $5.1 million and $5.0 million, respectively. For the three and six months ended June 30, 2017, net change in unrealized gain (loss) on the Company’s assets and liabilities totaled ($0.5) million and ($0.3) million, respectively. Net unrealized gain for the three months ended June 30, 2018 is primarily due to the reversal of previously recorded unrealized loss on our investment in Metamorph US 3, LLC, as well as appreciation on our investments in North Mill Capital LLC and Gemino Healthcare Finance, LLC, among others, partially offset by depreciation in First Lien Loan Program LLC, American Teleconferencing Services, Ltd. and Polycom, Inc., among others. Net unrealized gain for the six months ended June 30, 2018 is primarily due to the reversal of previously recorded unrealized loss on our investment in Metamorph US 3, LLC, as well as appreciation on our investments in North Mill Capital LLC and Gemino Healthcare Finance, LLC, among others, partially offset by depreciation in First Lien Loan Program LLC, PPT Management Holdings, LLC and Alteon Health, LLC, among others. Net unrealized loss for the three months ended June 30, 2017 is primarily due to depreciation in the value of our investments in Gemino Healthcare Finance, LLC, Metamorph US 3, LLC, and Anesthesia Consulting & Management, LP, among others, partially offset by appreciation in Hostway Corporation, Aegis Toxicology Sciences Corporation and QBS Holding Company, Inc., among others. Net unrealized loss for the six months ended June 30, 2017 is primarily due to depreciation in the value of our investments in Metamorph US 3, LLC, Gemino Healthcare Finance, LLC and Anesthesia Consulting & Management, LP, among others, partially offset by appreciation in Hostway Corporation, Securus Technologies, Inc. and American Teleconferencing Services, Ltd., among others.
Net Increase in Net Assets From Operations
For the three and six months ended June 30, 2018, the Company had a net increase in net assets resulting from operations of $5.5 million and $11.0 million, respectively. For the same periods, earnings per average share were $0.34 and $0.69, respectively. For the three and six months ended June 30, 2017, the Company had a net increase in net assets resulting from operations of $5.2 million and $11.1 million, respectively. For the same periods, earnings per average share were $0.33 and $0.70, respectively.
LIQUIDITY AND CAPITAL RESOURCES
The Company’s liquidity and capital resources are generally available through its Credit Facility, through periodicfollow-on equity offerings, as well as from cash flows from operations, investment sales andpre-payments of investments. At June 30, 2018, the Company had $185.9 million in borrowings outstanding on its Credit Facility and $14.1 million of unused capacity, subject to borrowing base limits.
In September 2016, the Company closed afollow-on public equity offering of 4.5 million shares of common stock at $16.76 per share raising approximately $75.0 million in net proceeds. In the future, the Company may raise additional equity or debt capital, among other considerations. The primary uses of funds will be investments in portfolio companies, reductions in debt outstanding and other general corporate purposes. The issuance of debt or equity securities will depend on future market conditions, funding needs and other factors and there can be no assurance that any such issuance will occur or be successful.
We currently expect that our liquidity needs will be met with cash flows from operations, borrowings under our Credit Facility, including its accordion feature, as well as from other available financing activities.
52